Endocyte Inc. (NASDAQ:ECYT) shares saw unusually-high trading volume on Friday . Approximately 154,084 shares were traded during trading, a decline of 5% from the previous session’s volume of 161,920 shares.The stock last traded at $3.28 and had previously closed at $3.21.

ECYT has been the subject of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Endocyte in a report on Wednesday, May 4th. Cowen and Company reaffirmed a “buy” rating on shares of Endocyte in a report on Wednesday, May 4th. Zacks Investment Research lowered shares of Endocyte from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating on shares of Endocyte in a report on Tuesday, July 12th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $11.15.

The stock’s market capitalization is $139.05 million. The stock’s 50-day moving average is $3.15 and its 200 day moving average is $3.41.

Endocyte (NASDAQ:ECYT) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.01. During the same period last year, the company posted ($0.25) earnings per share. On average, equities research analysts expect that Endocyte Inc. will post ($1.12) earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.